Belite Bio Details Phase 3 DRAGON Win as Tinlarebant Cuts Stargardt Lesion Growth 36% at Conference [Yahoo! Finance]
Belite Bio, Inc - American Depositary Shares (BLTE)
Company Research
Source: Yahoo! Finance
autofluorescence (DDAF) lesions in Stargardt disease by over two years (P=0.0033; structured covariance P Tinlarebant is an oral RBP4 antagonist that aims to lower retinal vitamin A delivery to prevent toxic bisretinal accumulation; the 5 mg once-daily dose reduced circulating retinol and RBP by about in early studies. Safety was generally manageable with mostly mild ophthalmic events (longer dark adaptation and transient visual discoloration); Belite is finalizing the clinical study report, plans an FDA submission in the first half of the year, and is preparing filings for the EMA MHRA while running Japan's DRAGON II and the PHOENIX GA trial. Interested in Belite Bio, Inc. Sponsored ADR? Here are five stocks we like better. 3 Lesser-Known Healthcare Names With Major Upside in Store Belite Bio (NASDAQ:BLTE) Chief Medical Officer Hendrik Scholl outlined the company's approach to treating Stargardt disease and reviewed top-line results from its Phase 3 DRAGON trial during a co
Show less
Read more
Impact Snapshot
Event Time:
BLTE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLTE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLTE alerts
High impacting Belite Bio, Inc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BLTE
News
- Belite Bio (BLTE) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=BLTE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" to "holMarketBeat
- Belite Bio price target raised to $266 from $200 at Cantor Fitzgerald [Yahoo! Finance]Yahoo! Finance
- Belite Bio (BLTE) was given a new $217.00 price target by Needham & Company LLC.MarketBeat
- Belite Bio (BLTE) had its price target raised by HC Wainwright from $185.00 to $200.00. They now have a "buy" rating on the stock.MarketBeat
- Belite Bio (BLTE) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
BLTE
Earnings
- 3/2/26 - Beat
BLTE
Sec Filings
- 3/18/26 - Form 3
- 3/18/26 - Form 3
- 3/18/26 - Form 3
- BLTE's page on the SEC website